Compare Flagstar Bank NA (FLG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs Vertex Pharmaceuticals Incorporated — how do they compare? Flagstar Bank NA trades at $11.36 (market cap $4.69B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 27.3× Flagstar Bank NA's market cap, and Flagstar Bank NA pays a 0.35% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Flagstar Bank NA for 21 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| FLG | VRTX | |
|---|---|---|
Market Cap | $4.69B | $128.16B |
Volume | 6,174,553 | 806,603 |
Sector | Financials | Health |
52-Week High | $15.36 | $557.96 |
52-Week Low | $10.72 | $407.37 |
Typical Hold Time | 21 Days | 120 Days |
Enterprise Value | $15.23B | $122.29B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLG trades at $11.30, down 2.25% today, with a bearish technical signal despite bullish oscillators. The stock shows mixed fundamentals with a high P/E of 376.67 but trades below book value (P/B 0.61). Recent Q2 2026 earnings missed expectations, though the company reported its third consecutive profitable quarter. Analyst consensus remains strongly bullish with a $17.07 price target and no sell ratings.
The outlook suggests potential upside from current depressed levels, supported by analyst optimism and strategic initiatives like the $250M share repurchase program. Key risks include earnings volatility, competitive pressures in regional banking, and sensitivity to interest rate changes. The stock presents a value opportunity but requires careful monitoring of execution on profitability targets.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
